Key facts
- This page summarizes Redmile Group, LLC's Form 4 filing for Entrada Therapeutics, Inc. (TRDA).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Nov 2021, 21:00.
Redmile Group, LLC - 02 Nov 2021 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- TRDA
- Reported as of
- 02 Nov 2021
- Net transaction value
- +$20,000,000
- SEC form
- 4
- Accepted by SEC
- 04 Nov 2021, 21:00:33 UTC
- Prior SEC filing
- 21 Apr 2023
- Next SEC filing
- 04 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeremy Green, Managing Member of Redmile Group, LLC
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Redmile Group, LLC filed Form 4 for Entrada Therapeutics, Inc. (TRDA) on 04 Nov 2021.
Change
- Previous filing in this sequence was filed on 21 Apr 2023.
- Current net transaction value: +$20,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TRDA
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +954,420
- Change %
- Price
- Shares after
- 954,420
- Date
- 02 Nov 2021
- Ownership
- See Footnote
- Footnotes
- F1, F2
TRDA
transaction
Common Stock
Purchase
- Transaction value
- $20,000,000
- Shares
- +1,000,000
- Change %
- +105%
- Price
- $20.00
- Shares after
- 1,954,420
- Date
- 02 Nov 2021
- Ownership
- See Footnote
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TRDA
transaction
Derivative
Series B Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -954,420
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 02 Nov 2021
- Ownership
- See Footnote
- Underlying class
- Common Stock
- Underlying amount
- 954,420
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Redmile Group, LLC is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
The Series B convertible preferred stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering for no consideration. The Series B convertible preferred stock had no expiration date.
Footnote F2
These securities are directly owned by certain private investment vehicles managed by Redmile Group, LLC ("Redmile"), including Redmile Biopharma Investments III, L.P., and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Footnote F3
Reflects number of shares owned as of November 2, 2021.